| 商品名称 | Emend |
|---|
| 适用类别 | Human |
|---|
| 治疗领域 | Vomiting;Postoperative Nausea and Vomiting;Cancer |
|---|
| 通用名/非专利名称 | aprepitant |
|---|
| 活性成分 | aprepitant |
|---|
| 产品号 | EMEA/H/C/000527 |
|---|
| 患者安全信息 | No |
|---|
| 许可状态 | Authorised |
|---|
| ATC编码 | A04AD12 |
|---|
| 是否额外监管 | No |
|---|
| 是否仿制药或hybrid药物 | No |
|---|
| 是否生物类似药 | No |
|---|
| 是否附条件批准 | No |
|---|
| 是否特殊情形 | No |
|---|
| 是否加速审评 | No |
|---|
| 是否罕用药 | No |
|---|
| 上市许可日期 | 2003/11/11 |
|---|
| 上市许可开发者/申请人/持有人 | Merck Sharp & Dohme B.V. |
|---|
| 人用药物治疗学分组 | Antiemetics and antinauseants |
|---|
| 兽用药物治疗学分组 | |
|---|
| 审评意见日期 | 2003/07/24 |
|---|
| 欧盟委员会决定日期 | 2025/10/24 |
|---|
| 修订号 | 33 |
|---|
| 治疗适应症 | Emend 40 mg hard capsules is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults. Emend is also available as 80 mg and 125 mg hard capsules for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and adolescents from the age of 12 (see separate Summary of Product Characteristics). Emend is also available as 165 mg hard capsules for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy in adults and the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults. Emend is also available as powder for oral suspension for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in children, toddlers and infants from the age of 6 months to less than 12 years. Emend 80 mg, 125 mg, 165 mg hard capsules and Emend powder for oral suspension are given as part of combination therapy. |
|---|
| 适用物种 | |
|---|
| 兽用药物ATC编码 | |
|---|
| 首次发布日期 | 2018/05/24 |
|---|
| 最后更新日期 | 2025/10/24 |
|---|
| 产品说明书 | https://www.ema.europa.eu/en/documents/product-information/emend-epar-product-information_en.pdf |
|---|
| 公共评估报告 | https://www.ema.europa.eu/en/medicines/human/EPAR/emend |
|---|